| 26.07 15:47 | dpa-AFX: *BIOGEN -5,2% - EMA VERWEIGERT ZULASSUNG EINES ALZHEIMER-MITTELS |
| 26.07 15:33 | dpa-AFX: Biogen Falls After Receiving Negative Opinion From CHMP For Lecanemab For Early Alzheimer's Disease |
| 26.07 15:04 | dpa-AFX: ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab |
| 26.07 15:04 | ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab |
| 26.07 14:59 | dpa-AFX: ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab |
| 26.07 13:30 | dpa-AFX: *EISAI AND BIOGEN : CHMP ISSUES NEGATIVE OPINION ON LECANEMAB FOR EARLY ALZHEIMER'S DISEASE |
| 26.07 13:20 | dpa-AFX: GNW-Adhoc: Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
| 24.07 12:56 | dpa-AFX: Sage Therapeutics, Biogen Say Phase 2 KINETIC 2 Study Of SAGE-324 In Essential Tremor Fails |
| 24.07 12:35 | dpa-AFX: *SAGE THERAPEUTICS, BIOGEN: TOPLINE RESULTS FROM PHASE 2 KINETIC 2 STUDY OF SAGE-324 FAILS TO MEET END POINT |
| 02.07 15:47 | dpa-AFX: *BIOGEN CLOSES ACQUISITION OF HUMAN IMMUNOLOGY BIOSCIENCES |
| 02.07 15:16 | dpa-AFX: GNW-Adhoc: Biogen Completes Acquisition of Human Immunology Biosciences |
| 28.06 01:39 | dpa-AFX: GNW-Adhoc: "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
| 24.06 14:22 | dpa-AFX: Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications |
| 24.06 13:57 | dpa-AFX: *BIOGEN'S TOFIDENCE BIOSIMILAR RECEIVES EC APPROVAL FOR MULTIPLE INDICATIONS INCL. COVID-19 TREATMENT |
| 24.06 13:30 | dpa-AFX: GNW-Adhoc: TOFIDENCET (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union |
| 10.06 07:07 | dpa-AFX: *BIOGEN SAYS FDA ACCEPTS EISAI'S SBLA FOR MONTHLY LECANEMAB-IRMB IV MAINTENANCE DOSING |
| 10.06 02:48 | dpa-AFX: Eisai : FDA Accepts SBLA On LEQEMBI For Early Alzheimer's Treatment |
| 10.06 01:37 | dpa-AFX: GNW-Adhoc: FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| 06.06 12:37 | Italienische Wettbewerbsbehörde nimmt vier Pharmakonzerne ins Visier |
| 31.05 04:16 | dpa-AFX: Biogen : EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis |
|
|
